Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Mega Lifesciences Management

Management Kriterienprüfungen 2/4

Mega Lifesciences' CEO ist Vivek Dhawan, ernannt in Jan 1988, hat eine Amtszeit von 36.33 Jahren. besitzt direkt 6.62% der Aktien des Unternehmens, im Wert von THB2.34B. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 26.3 Jahre bzw. 11.3 Jahre.

Wichtige Informationen

Vivek Dhawan

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	36.4yrs
Eigentum des Geschäftsführers	6.6%
Durchschnittliche Amtszeit des Managements	26.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.3yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Vivek Dhawan (63 yo)

36.4yrs

Amtszeit

Mr. Vivek Dhawan has been the Chief Executive Officer of Mega Lifesciences Public Company Limited since 1988 and has been its Chief Coach since 2013. Mr. Dhawan started with Medicap and built Lupin Laborat...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Vivek Dhawan	CEO, Chief Coach & Executive Director	36.4yrs	keine Daten	6.62% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.4yrs	keine Daten	0.76% THB 255.1m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	keine Daten	keine Daten
Paramjit Sawhney	President of International	no data	keine Daten	1.5% THB 500.5m
Girish Wadhwa	President of Myanmar	no data	keine Daten	keine Daten
Manoj Gurbuxani	Deputy Chief Financial Officer	4.4yrs	keine Daten	0.000010% THB 3.3k
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	keine Daten	1.48% THB 492.8m
Sujintana Boonworapat	Corporate Secretary	no data	keine Daten	0.021% THB 6.9m

26.4yrs

Durchschnittliche Betriebszugehörigkeit

57.5yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von MEGA ist erfahren und erfahren (durchschnittliche Amtszeit: 26.3 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Vivek Dhawan	CEO, Chief Coach & Executive Director	11.4yrs	keine Daten	6.62% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.4yrs	keine Daten	0.76% THB 255.1m
Yim Chi	Independent Vice Chairma	11.3yrs	฿1.58m	keine Daten
Kirit Chimanlal Shah	Non-Executive Director	11.3yrs	฿661.50k	50.13% THB 16.7b
Shiraz Poonevala	Non-Executive Director	11.3yrs	฿661.50k	keine Daten
Ishaan Shah	Non-Executive Director	11.3yrs	฿661.50k	keine Daten
Mechai Viravaidya	Independent Chairman	11.3yrs	฿2.21m	keine Daten
Sameera Shah	Non-Executive Director	11.3yrs	฿661.50k	keine Daten
Thor Santhisiri	Independent Director	11.3yrs	฿1.15m	0.013% THB 4.2m
Vijay Karwal	Independent Director	3.1yrs	฿1.15m	keine Daten
Nithinart Sinthudeacha	Independent Director	1.4yrs	฿1.15m	keine Daten

11.3yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: MEGADie Vorstandsmitglieder sind sehr erfahren ( 11.3 ).

Mega Lifesciences Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter